Skip to main content
ANNX
NASDAQ Life Sciences

Shareholders to Vote on 123% Potential Dilution via Authorized Share Increase

Analysis by Wiseek.ai
Sentiment info
Negative
Importance info
9
Price
$6.33
Mkt Cap
$1.016B
52W Low
$1.4
52W High
$7.18
Market data snapshot near publication time

summarizeSummary

Annexon, Inc. proposes a significant increase in authorized common stock, potentially leading to over 123% dilution, citing a need for future financing and potential use in takeover defense.


check_boxKey Events

  • Proposed Increase in Authorized Shares

    The company is asking shareholders to approve an amendment to its Certificate of Incorporation to increase the number of authorized common stock from 300,000,000 to 500,000,000 shares.

  • Significant Potential Dilution

    If all 200,000,000 newly authorized shares were issued, it would represent a potential dilution of over 123% compared to the 162,507,278 shares currently outstanding.

  • Stated Need for Future Financing

    The rationale for the increase includes the need for additional financing to fund working capital and obligations, suggesting upcoming capital raises.

  • Anti-Takeover Implications

    The company acknowledges that the additional shares could be used to oppose hostile takeover attempts or delay changes in control.


auto_awesomeAnalysis

Annexon, Inc. is seeking shareholder approval to significantly increase its authorized common stock from 300,000,000 to 500,000,000 shares. This proposed 200,000,000 share increase represents a potential dilution of over 123% relative to the current 162,507,278 outstanding shares. The company explicitly states the need for additional financing to fund working capital and obligations, indicating a critical need for capital that could lead to substantial future equity raises. Furthermore, the filing notes that these additional shares could be used to deter hostile takeover attempts, which may be viewed negatively by shareholders.

At the time of this filing, ANNX was trading at $6.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $1.40 to $7.18. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed ANNX - Latest Insights

ANNX
Apr 16, 2026, 4:06 PM EDT
Filing Type: PRE 14A
Importance Score:
9
ANNX
Mar 30, 2026, 7:42 PM EDT
Filing Type: S-3ASR
Importance Score:
7
ANNX
Mar 30, 2026, 5:30 PM EDT
Filing Type: 10-K
Importance Score:
7
ANNX
Mar 30, 2026, 5:29 PM EDT
Filing Type: 8-K
Importance Score:
8
ANNX
Mar 30, 2026, 4:01 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
ANNX
Mar 30, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
ANNX
Jan 14, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
8
ANNX
Jan 12, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
8